Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Cancer Drug Confirmatory Trials Should Be Initiated Early, FDA Says

Executive Summary

FDA is urging sponsors of cancer drugs undergoing accelerated approval to initiate confirmatory studies early to avoid problems in completing trials often seen after approval

You may also be interested in...



FDA Will Make Advisory Committee Review Of Accelerated Approvals An Annual Event

FDA plans to hold a yearly session with its Oncology Drugs Advisory Committee on cancer drugs granted accelerated approval as a means of holding sponsors' feet to the fire with regard to conducting confirmatory trials.

FDA Will Make Advisory Committee Review Of Accelerated Approvals An Annual Event

FDA plans to hold a yearly session with its Oncology Drugs Advisory Committee on cancer drugs granted accelerated approval as a means of holding sponsors' feet to the fire with regard to conducting confirmatory trials.

Pfizer Pulls Mylotarg For Safety 10 Years After Accelerated Approval

Although Pfizer's voluntary withdrawal of its acute myeloid leukemia therapy Mylotarg is the first complete withdrawal of an accelerated approval NDA, but as in other cases where the confirmatory trial fails to substantiate the initial signs of efficacy that supported the accelerated approval, FDA is not completely closing the door on access to the drug

Related Content

UsernamePublicRestriction

Register

PS041464

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel